Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efgartigimod and Pneumovax 23 immune response in healthy volunteers
NCT05163834Phase 1Completed
- Sponsor
- argenx
- Start
- Nov 2021
- Primary completion
- Mar 2022
- Modality
- Antibody Fragments
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of efgartigimod alfa in myasthenia gravis (MG) (3 arms), sponsored by argenx. Primary endpoint: Pneumococcal Capsular Polysaccharide titers up to 12 weeks. Started Nov 2021; status: completed.
02
Drugs
efgartigimod alfa
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on NCT05163834.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05163834.